WISeKey Intl Holding (OTC:WSKEF) Stock, Quote.Headers.trade-ideas

WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAEEF

AAPT

ACMUY

AEMD

AGTK

AKRX

AMNL

BGOUF

BKPPF

BRTX

BYZN

CANSF

CANWF

CBGZF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CBYDF

CCNCF

CNBX

CPAH

CPNFF

CRCW

CXRXF

DECN

DECXF

DLOC

DXBRF

EANRF

EKSO

ELGX

ELLXF

FPAFY

FRLF

FTFT

GALT

GCFB

GTCH

GTII

GWRRF

HIPH

HPIL

INNT

IRNC

JXMNF

KMPH

KRKR

LESAF

LGDDF

LTMCF

MAOMF

MAYS

MGEN

MITO

MLXEF

MMJJF

NABIF

NAKD

NMHLY

NOSOF

NSUPF

NXTTF

OIBRQ

OTEL

PHMB

PRVU

PTOTF

QMC QUANTUM MINERALS CORP by QMC Quantum Minerals Corp.

QMCQF

RGRNF

RMIOF

ROYL

RPNMF

SEED

SZCRF

TCON

THTX

TOMDF

TOWER ONE WIRE ORD (A) by Tower One Wireless Corp

TOWTF

UDIRF

UFMG

VLRX

WATT

WCVC

WDDMF

WECFF

WLSI

WSKEF

ZSAN

MGXRF

Stocks That Hit 52-Week Lows On Friday

ABWN

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AQMS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHX

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

ATYG

BGFT

BLOZF

BOIRF

BWLVF

CBRI

CCGN

CHMR

CMGHF

COCP

CORV

COTE

CSPUF

DVLY

DYLLF

ECOR

FERL

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

FVGCF

FVVSF

GGBXF

GLBS

GTBP

GURE

HEMP

HESG

HGEN

HKTTF

HUABF

HVBTF

ICABY

IPSEY

ISIG

IWSY

KINS

LATF

LFUGF

LFUGY

MCET

MDIN

MGXMF

MIST

MOAEF

NHNKY

NIMU

OCANF

OGDCF

OLVRF

PARNF

PHAT

PHTCF

PHUN

PMSO

PRTR

PSIX

QBAN

QEGY

QOIL

RETC

RKAGY

RTTR

RVLT

SEEK

SFEG

SING

SNNAF

SPVNF

SUIC

TBEV

TGIFF

TLGN

TLRY

TOCA

TRPX

TWMC

UBQU

UVSE

VFRM

VGGOF

VREOF

VVCIF

WHITF

ICC INTL CANNABIS CORP by ICC Intl Cannabis Corp.

WLDCF

Stocks That Hit 52-Week Lows On Wednesday

WISEKEY INTL HLDGS LTD by WISeKey International Holding Ltd.

WISeKey International Holding Ltd

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). Results were shared during an oral session at the American Society of Hematology (ASH) 2024 Annual Meeting and support continued development of poze-cemdi in PNH, including in a separate registrational cohort, as well as in other complement-mediated diseases. Poze-Cemdi is a first-in-class combination of an antibody and an siRNA targeting C5: pozelimab is a fully human monoclonal antibody designed to block the activity of C5, while cemdisiran is an investigational siRNA therapeutic that reduces circulating levels of C5.
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab
Five patients receiving ravulizumab did not achieve meaningful LDH control compared to one patient receiving poze-cemdi; after switching to the combination, four of the five previously treated with ravulizumab achieved LDH control
A separate registrational cohort is ongoing, investigating poze-cemdi against eculizumab

REGN

- Regeneron Announced Novel Combination Of Pozelimab And Cemdisiran Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Vs Ravulizumab

Comments

WISeKey Intl Holding

WISeKey Intl Holding (WSKEF) Forecast

WISeKey Intl Holding (OTC:WSKEF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga